fibrinoid necrosis in a rhesus macaque
DESCRIPTION
Fibrinoid necrosis in a Rhesus macaque. Karen Strait, Dan Anderson, and Elizabeth Strobert Yerkes National Primate Research Center Emory University. History. Signalment: ~5 year old, male, rhesus macaque Assigned to renal transplant study - PowerPoint PPT PresentationTRANSCRIPT
Fibrinoid necrosis Fibrinoid necrosis in a Rhesus in a Rhesus
macaquemacaque
Karen Strait, Dan Anderson, and Karen Strait, Dan Anderson, and Elizabeth StrobertElizabeth Strobert
Yerkes National Primate Research Yerkes National Primate Research CenterCenter
Emory UniversityEmory University
Presented at SEVPAC 2008 – Permission granted for use on SEVPAC
website only
HistoryHistory
Signalment: ~5 year old, male, rhesus Signalment: ~5 year old, male, rhesus macaquemacaque
Assigned to renal transplant study Assigned to renal transplant study Left nephrectomy followed by right Left nephrectomy followed by right
nephrectomy and allogeneic renal nephrectomy and allogeneic renal transplant 5 months latertransplant 5 months later
Received sirolimus and Cremophor EL Received sirolimus and Cremophor EL vehicle beginning the day of vehicle beginning the day of transplantationtransplantation
ControlControlPresented at SEVPAC 2008 –
Permission granted for use on SEVPAC website only
HistoryHistory
Clinical findings following renal transplantClinical findings following renal transplant Right kidney prominent and firmRight kidney prominent and firm Scrotal edema/perineal edema, absent by post-op Scrotal edema/perineal edema, absent by post-op
day 14day 14 Intermittent diarrheal episodes, treated with Intermittent diarrheal episodes, treated with
appropriate antibioticsappropriate antibiotics Occasional periorbital edemaOccasional periorbital edema Thrombocytopenia at day 38 post-opThrombocytopenia at day 38 post-op Poor appetite/weight loss at 40 days post-opPoor appetite/weight loss at 40 days post-op
Animal euthanized due to a deteriorating Animal euthanized due to a deteriorating clinical conditionclinical condition
Presented at SEVPAC 2008 – Permission granted for use on SEVPAC
website only
Gross FindingsGross Findings
Presented at SEVPAC 2008 – Permission granted for use on SEVPAC
website only
Gross findingsGross findings
Presented at SEVPAC 2008 – Permission granted for use on SEVPAC
website only
HistopathologyHistopathology
Presented at SEVPAC 2008 – Permission granted for use on SEVPAC
website only
HistopathologyHistopathology
Presented at SEVPAC 2008 – Permission granted for use on SEVPAC
website only
HistopathologyHistopathology
Presented at SEVPAC 2008 – Permission granted for use on SEVPAC
website only
HistopathologyHistopathology
Presented at SEVPAC 2008 – Permission granted for use on SEVPAC
website only
HistopathologyHistopathology
Presented at SEVPAC 2008 – Permission granted for use on SEVPAC
website only
HistopathologyHistopathology
Presented at SEVPAC 2008 – Permission granted for use on SEVPAC
website only
DiagnosisDiagnosis
Morphologic diagnosisMorphologic diagnosis: multifocal : multifocal severe fibrinoid necrosis of severe fibrinoid necrosis of submucosal arteries with edema and submucosal arteries with edema and thickening of associated tissues thickening of associated tissues
Presented at SEVPAC 2008 – Permission granted for use on SEVPAC
website only
DiscussionDiscussion
Cause is undeterminedCause is undetermined Possible association with drug Possible association with drug
regimen in this animal modelregimen in this animal model
Presented at SEVPAC 2008 – Permission granted for use on SEVPAC
website only
DiscussionDiscussion SirolimusSirolimus
Immunosuppressive/ anti-rejection drugImmunosuppressive/ anti-rejection drug Non-nephrotoxicNon-nephrotoxic Fibrinoid necrosis in GI previously reported Fibrinoid necrosis in GI previously reported
in rhesus macaques receiving sirolimus, in rhesus macaques receiving sirolimus, tacrolimus, and daclizumab to prevent renal tacrolimus, and daclizumab to prevent renal allograft rejection – attributed to sirolimus allograft rejection – attributed to sirolimus toxicitytoxicity
Link between sirolimus and fibrinoid necrosis Link between sirolimus and fibrinoid necrosis shown in some species, absent in othersshown in some species, absent in others
Not seen in other transplant studies at Not seen in other transplant studies at YerkesYerkes
Presented at SEVPAC 2008 – Permission granted for use on SEVPAC
website only
DiscussionDiscussion
Cremophor ELCremophor EL Vehicle for hydrophobic drugsVehicle for hydrophobic drugs Not inertNot inert May change pharmacological profile of May change pharmacological profile of
drugs administered with itdrugs administered with it Unknown interaction between Unknown interaction between
Cremophor EL and sirolimus Cremophor EL and sirolimus Fibrinoid necrosis not reported with this Fibrinoid necrosis not reported with this
drugdrug Combination of animal model, Combination of animal model,
sirolimus and Cremophor EL??sirolimus and Cremophor EL??Presented at SEVPAC 2008 – Permission granted for use on SEVPAC
website only
AcknowledgementsAcknowledgements
Eileen BredingEileen Breding Evan DessasauEvan Dessasau
Presented at SEVPAC 2008 – Permission granted for use on SEVPAC
website only
ReferencesReferences
1. Gelderblom, H., J. Verweij, K. Nooter, A. 1. Gelderblom, H., J. Verweij, K. Nooter, A. Sparreboom. 2001. Cremophor EL: the Sparreboom. 2001. Cremophor EL: the drawbacks and advantages of vehicle drawbacks and advantages of vehicle selection for drug formulation. selection for drug formulation. Eur J CancerEur J Cancer. . 37(13):1590-8.37(13):1590-8.
2. Montgomery, S.P., S.R. Mog, H. Xu, D.K. 2. Montgomery, S.P., S.R. Mog, H. Xu, D.K. Tadaki, B. Hirshberg, J.D. Berning, J. Leconte, Tadaki, B. Hirshberg, J.D. Berning, J. Leconte, D.M. Harlan, D. Hale, A.D. Kirk. 2002. D.M. Harlan, D. Hale, A.D. Kirk. 2002. Efficacy and toxicity of a protocol using Efficacy and toxicity of a protocol using sirolimus, tacrolimus, and daclizumab in a sirolimus, tacrolimus, and daclizumab in a nonhuman primate renal allotransplant model. nonhuman primate renal allotransplant model. Am J TransplantAm J Transplant. 2(4):381-5.. 2(4):381-5.Presented at SEVPAC 2008 –
Permission granted for use on SEVPAC website only
Questions?Questions?
Presented at SEVPAC 2008 – Permission granted for use on SEVPAC
website only